Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SinuSurf is a topical sinonasal surfactant that was previously commercially available and investigated for use in the management of recalcitrant chronic rhinosinusitis. It is not a pharmaceutical drug in the traditional sense but rather a surfactant solution designed to be used as an adjunctive therapy during sinonasal irrigation. SinuSurf demonstrated significant in vitro antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, including reduction of biofilm formation by these pathogens. The addition of SinuSurf to topical antibiotics such as mupirocin or gentamicin improved their effectiveness at lower concentrations, suggesting potential utility for patients with chronic rhinosinusitis complicated by resistant bacterial biofilms[7]. The exact composition and mechanism are based on its surfactant properties, which disrupt microbial membranes and biofilms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sinusurf.